J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?
TL;DR: ICON 4, the first large-scale randomised trial in ‘platinum-sensitive’ relapsed ovarian cancer demonstrated a survival benefit for using platinum-based therapy in combination with paclitaxel, and more studies are needed to explore other combinations of treatment in this group of women.
Journal ArticleDOI
International Journal of Gynecological Cancer. Editorial.
Journal ArticleDOI
Do Cell-Cycle Phase-Specific Markers Predict Disease Grade, Stage, and Outcome in Cervical Carcinoma?
Stephanie Kuku,Ian Proctor,Marco Loddo,Latha Kadalayil,Mohammad KhoshZaban,Jonathan A. Ledermann,Mary McCormack +6 more
TL;DR: Cell cycle phase–specific markers do not appear to predict disease grade, stage, or outcome in a sample of patients with cervical cancer, which raises many interesting questions including the prognostic value of disease grade and markers of proliferation in cervical tumors as reliable prognostic indicators.
Journal ArticleDOI
O-0018chronicle: a phase iii trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine/oxaliplatin versus control
Rob Glynne-Jones,Nicholas Counsell,Helen Meadows,Jonathan A. Ledermann,David Sebag-Montefiore +4 more
Journal ArticleDOI
ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer.
Jane Hook,S. P. Stenning,James D. Brenton,Stan B. Kaye,Iain A. McNeish,Raj Naik,Timothy J. Perren,Jennifer Petrie,Laura Farrelly,Andrew Dean,Dearbhaile M. O'Donnell,Dolores Gallardo Rincon,Jae Weon Kim,Jonathan A. Ledermann,Andrew R Clamp +14 more
TL;DR: ICON8 is the largest trial of dose-dense therapy in ovarian cancer and will compare the efficacy and safety of CT with CwT and wCwT regimens, open at 111 centres in the UK, S Korea, Mexico, Ireland, Australia and New Zealand.